$1.56
-0.02-1.27%
Last update: Oct 23, 9:25 AM
enGene Therapeutics Inc (ENGN) Stock Price, Quote, News & History
ENGNNASDAQ
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
You can purchase shares of enGene Therapeutics (NASDAQ:ENGN) through any online brokerage.
Other companies in enGene Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
enGene Therapeutics has a consensus price target of $18.04.
The stock price for enGene Therapeutics (NASDAQ: ENGN) is $1.57 last updated October 23, 2026 at 9:25 AM EDT.
There are no upcoming dividends for enGene Therapeutics.
enGene Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for enGene Therapeutics.
enGene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering...
